Comparing the effect of glatiramer acetate 20 mg vs glatiramer acetate 40 mg on retinal structures in patients with relapsing remitting multiple sclerosis
Author(s): ,
M. Gilroy
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
R. Darling
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
S. Lichtman-Mikol
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
S. Razmjou
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
E. Probst-Simmons
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
C. Santiago-Martinez
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
E. Bernitsas
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
ECTRIMS Online Library. Santiago-Martinez C. Oct 12, 2018; 228996; P1156
Carla Santiago-Martinez
Carla Santiago-Martinez
Contributions
×
Abstract

Abstract: P1156

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - OCT

Objective: To compare the effect of glatiramer acetate 20 mg (GA20) daily injection vs glatiramer acetate 40 mg (GA40) three times a week on retinal structures in patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Background: The efficacy and safety of glatiramer acetate subcutaneous injections has been well established in MS patients. GA40 injection is administered three times a week and is more favorable over GA20 daily injections. As retinal thickness decreases in MS patients over time, it is important to compare the effect of each treatment on retinal structures.
Design/Methods: 29 RRMS patients on GA20 mg daily injections (23 women, 6 men) and 18 RRMS patients on GA40 mg injections three times a week (12 women, 6 men) were included in this cross-sectional analysis. The mean age ±SD were 48.3 ±7.4 and 43.8 ±8.8 for GA20 and GA40, respectively. Optical coherence tomography (OCT) was performed by an experienced technician to quantify the papillomacular bundle (PMB) and the peripapillary retinal nerve fiber layer (pRNFL) quadrant thicknesses: superior, inferior, temporal, nasal. Intra-retinal segmentation was performed to obtain total macular volume (TMV), retinal nerve fiber (RNFL), ganglion cell (GCL), inner plexiform (IPL), inner nuclear (INL), outer plexiform (OPL) and outer nuclear (ONL) layer thickness.​ A generalized linear model with OCT parameters as dependent variables and treatment groups as independent variable was used to analyze our data. Age, disease duration, sex and race were all included as covariates. (SPSS vs 24).
Results: There was no significant difference in retinal thickness between GA20 and GA40. The mean global pRNFL thickness was 91.6 ±12.9 and 95.2 ±11.8 in GA20 and GA40, respectively (p=0.48). The mean RNFL thickness was 0.79 ±0.13 in patients on GA20 and 0.82 ±0.12 in the GA40 group without a significant group difference (p=0.51).
Conclusion: Our study demonstrates similar effectiveness of GA20 and GA40 on retinal structures in RRMS patients. Because GA40 is a three times/week injection as opposed to GA20 daily injections, GA40 is a favorable, more convenient treatment option for RRMS patients.
Disclosure: Evanthia Bernitsas: DMC Foundation, Roche/Genetech, Sanofi/Genzyme, Biogen, Novartis, Chugai, Medimmune, EMD Serono. Melody Gilroy, Rachel Darling, Sara Razmjou, Samuel Lichtman-Mikol, Ellyse Probst-Simmons and Carla Santiago-Martinez: All have nothing to disclose.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies